Canaccord Genuity Reaffirms Buy Rating on Amicus Therapeutics (FOLD)

By admin | 6 years ago

Amicus Therapeutics (NASDAQ: FOLD)‘s stock had its “buy” rating reaffirmed by research analysts at Canaccord Genuity in a report released on Friday.

Shares of Amicus Therapeutics opened at 4.72 on Friday. Amicus Therapeutics has a one year low of $2.10 and a one year high of $8.12. The company’s market cap is $164.4 million.

Separately, analysts at JPMorgan Chase (NYSE: JPM) upgraded shares of Amicus Therapeutics from a “neutral” rating to an “overweight” rating in a research note to investors on Tuesday, May 8th.

Amicus Therapeutics, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of orally-administered, small molecule drugs known as pharmacological chaperones.

About the author